XXXX年中国制药远景与细节

1©2010Foley&LardnerLLP•AttorneyAdvertising•Priorresultsdonotguaranteeasimilaroutcome•Modelsusedarenotclientsbutmayberepresentativeofclients•321N.ClarkStreet,Suite2800,Chicago,IL60654•312.832.4500©2010Foley&LardnerLLP©2010Foley&LardnerLLP2InnovationManagementandInnovationManagementandTechnologyTransferinChina:TechnologyTransferinChina:TheBigPictureAndTheLittleDetailsTheBigPictureAndTheLittleDetailsJuly22,20102©2010Foley&LardnerLLP•AttorneyAdvertising•Priorresultsdonotguaranteeasimilaroutcome•Modelsusedarenotclientsbutmayberepresentativeofclients•321N.ClarkStreet,Suite2800,Chicago,IL60654•312.832.4500©2010Foley&LardnerLLP3PresentersPanelistGuangYang,Ph.D.AssociateDirectorPlatformTechnology,GlaxoSmithKline(China)R&DCo.,Ltd.Shanghai,P.R.ChinaPanelistGregB.ScottFounderandPresident,ChinaBio®LLCShanghai,P.R.ChinaSanDiego,CaliforniaPanelistJamesC.ChapmanPartner,Foley&LardnerLLPSiliconValley,CaliforniaModeratorJamesF.EwingPartner,Foley&LardnerLLPViceChair,Chemical,Biotechnology&PharmaceuticalPracticeBoston,Massachusetts©2010Foley&LardnerLLP4Science-TechnologyDevelopmentGuidelines(2006-2020)QNationalmedium-andlong-termprogramsforscienceandtechnologydevelopmentQBy2020,investmentsinresearchanddevelopmentprojectedtobe2.5percentofGDPQDevelopfrontiertechnologiesinsectorssuchasbiology,informationindustry,materialstechnologiesandadvancedmanufacturingtechnologyQChinatourgelargeenterprisestosetupresearchanddevelopment(R&D)institutesXinhuaNewsAgencyFebruary9,2006;©2010Foley&LardnerLLP•AttorneyAdvertising•Priorresultsdonotguaranteeasimilaroutcome•Modelsusedarenotclientsbutmayberepresentativeofclients•321N.ClarkStreet,Suite2800,Chicago,IL60654•312.832.4500©2010Foley&LardnerLLP5TheFive-YearPlanforNationalEconomicandSocialDevelopmentQArrangesnationalkeyconstructionprojectsQManagesthedistributionofproductiveforcesandindividualsector’scontributionstothenationaleconomyQMapsthedirectionoffuturedevelopmentQSetstargets©2010Foley&LardnerLLP6MajorHigh-techProjects(2006-2010)QIntegratedcircuitsandsoftwareQNew-generationnetworkQAdvancedcomputing:QBiomedicineQCivilairplaneQSatelliteapplicationQNewmaterials:high-performanceinformation,biologicalandaerospaceindustries4©2010Foley&LardnerLLP•AttorneyAdvertising•Priorresultsdonotguaranteeasimilaroutcome•Modelsusedarenotclientsbutmayberepresentativeofclients•321N.ClarkStreet,Suite2800,Chicago,IL60654•312.832.4500©2010Foley&LardnerLLP7AgendaQHowisthecommercializationofnewtechnologyreallyviewedinChina?QWhoarethegatekeeperstotechnology?QWhereinChinaistechnologybeingdeveloped?QOverviewoflifesciencetechnologydevelopmentinChina.QWhatarethepotentialpitfallswhenpartneringtodevelopnewtechnologyinChina?QHowcancompaniesstructuredealstomitigateoravoiddisputesdowntheroad?©2010Foley&LardnerLLP8RealitiesofCommercializingRealitiesofCommercializingTechnologyinChinaTechnologyinChina5©2010Foley&LardnerLLP•AttorneyAdvertising•Priorresultsdonotguaranteeasimilaroutcome•Modelsusedarenotclientsbutmayberepresentativeofclients•321N.ClarkStreet,Suite2800,Chicago,IL60654•312.832.4500©2010Foley&LardnerLLP9CommercializationofNewTechnologyinChinaQHowisthecommercializationofnewtechnologyreallyviewedinChina?WhoarethegatekeeperstotechnologyinChina?–Highly(oroverly)encouragedbutlooselyregulated:PIvs.TTO(centralizedvs.networks)–Formingmutuallybeneficialalliances:practicalandflexiblebusinessmodels(Hitechparks,localpharmaceutical/biotechcompanies)©2010Foley&LardnerLLP10MegaNewDrugDevelopmentProgramQFirstChinagovernmentprogramdedicatedsolelytodrugdevelopmentQMorethan$12Bavailableover5yearsQProgramledbyMOSTandMOH–Newdrugs,newprocesses,newplatformsfordrugdevelopment–Oncology,CVD,CNS,diabetes,immunology,andinfectiousdiseaseQOver$1BUSgrantedthusfarto53universities/institutesQUltimately–1000projects,200+companies10Source:ChinaBio®Consulting6©2010Foley&LardnerLLP•AttorneyAdvertising•Priorresultsdonotguaranteeasimilaroutcome•Modelsusedarenotclientsbutmayberepresentativeofclients•321N.ClarkStreet,Suite2800,Chicago,IL60654•312.832.4500©2010Foley&LardnerLLP11CommercializationofNewTechnologyinChina(cont.)QUsefulWebsites:–ChinaNationalCenterforBiotechnologyDevelopment:–TheMinistryofScienceandTechnologyofthePeople’sRepublicofChina:://–ChinaScienceandTechnologyNetwork:©2010Foley&LardnerLLP12TechnologyCategories(ImportandExport)QProhibitedQRestricted(requiresapprovalofMOFCOM)QPermitted(agreementmustberegisteredwithMOFCOMbutthereisnosubstantivereview)7©2010Foley&LardnerLLP•AttorneyAdvertising•Priorresultsdonotguaranteeasimilaroutcome•Modelsusedarenotclientsbutmayberepresentativeofclients•321N.ClarkStreet,Suite2800,Chicago,IL60654•312.832.4500©2010Foley&LardnerLLP13ChineseGovernmentApprovalQApprovalProcess–ApplicationforImportingPRCRestrictedTechnology–Within30businessdaysMOFCOMmustapproveorrejecttheapplication–Uponapproval,MOFCOMissuesProposalforTechnologyImportLicenseofthePRC–Partiesmaysig